Mariner LLC Acquires 42,089 Shares of Gilead Sciences, Inc. $GILD

Mariner LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 664,330 shares of the biopharmaceutical company’s stock after acquiring an additional 42,089 shares during the quarter. Mariner LLC’s holdings in Gilead Sciences were worth $81,547,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of GILD. Paulson Wealth Management Inc. raised its position in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares during the last quarter. Essex Financial Services Inc. raised its position in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Alpha Cubed Investments LLC raised its position in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 75 shares during the last quarter. Personal CFO Solutions LLC raised its position in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its position in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 76 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 62,000 shares of company stock worth $8,182,190. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $124.30 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The stock’s 50 day moving average price is $132.86 and its 200-day moving average price is $134.32. The company has a market capitalization of $154.33 billion, a PE ratio of 16.93 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Jefferies Financial Group assumed coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Wednesday, May 20th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.